# US 2003/0215387 A1 · Bifunctional antibodies and their use in targeting anti-tumour agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0215387 A1
- Document ID: US20030215387A1
- Status: Published application
- Kind: A1
- Application number: 10/445,132
- Filed: 2003-05-22
- Published: 2003-11-20
- Earliest claimed: 1998-09-04
- Inventors: Peter Harrison
- Web page: https://patentgrep.com/patent/US20030215387A1

## CPC

- C07K 16/30: from tumour cells
- C07K 16/18: against material from animals or humans
- C07K 2317/31: multispecific
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

A bifunctional antibody has affinity for a target site and affinity for an organic molecule covalently linked to a cytotoxic agent or an enzyme capable of converting a prodrug into its cytotoxic form. The antibody may be used in therapy or diagnosis, especially in the treatment of tumours.

## Claims

### Claim 1

A bifunctional antibody having affinity for a tumour and for a therapeutic or diagnostic agent, wherein the agent is an organic molecule.

### Claim 2 (depends on 1)

The bifunctional antibody, according to claim 1, wherein the agent is covalently-bound to an enzyme.

### Claim 3 (depends on 1)

The antibody according to claim 1, wherein the ligand-affinity is at least 1010 l/mol.

### Claim 4 (depends on 1)

The antibody according to claim 1, wherein the agent has a molecular weight of less than 1500.

### Claim 5 (depends on 1)

The antibody according to claim 1, wherein the agent is water-soluble and has a neutral biodistribution in vivo.

### Claim 6 (depends on 1)

The antibody according to claim 1, wherein the agent is radio-labeled and the radio-label is I123, I124, I125, P32 or I131.

### Claim 7 (depends on 1)

The antibody according to claim 1, wherein the agent is radiolabelled 4,4-bis(4-hydroxy-3,5-diiodophenyl) pentanoic acid.

### Claim 8 (depends on 1)

The antibody according to claim 1, wherein the organic molecule has the formula
3
where R1 and R2 are, independently a radiolabel, a methyl group or a phenyl group, and X1 and X2 are, independently, H or OH.

### Claim 9 (depends on 8)

The antibody according to claim 8, wherein the agent is radiolabelled N-(4-hydroxy-3,5-diiodobenzoyl)-1,6-hexanediamine or N-(2-hydroxy-3,5-diiodobenzoyl)-1,6-hexanediamine.

### Claim 10 (depends on 1)

The antibody according to claim 1, wherein the agent is biotin.

### Claim 11 (depends on 1)

The antibody according to claim 1, wherein the antibody affinity for the tumour is via a tumour-associated antigen.

### Claim 12 (depends on 11)

The antibody according to claim 11, wherein the antigen is carcinoembryonic antigen.

### Claim 13 (depends on 1)

The antibody according to claim 1, wherein the antibody comprises two single chain Fvs.

### Claim 14 (depends on 1)

The antibody according to claim 1, wherein the antibody comprises at least the constant regions derived from human immunoglobulin.

### Claim 15

A product comprising a bifunctional antibody having affinity for a tumour and for a therapeutic or diagnostic agent which is an organic molecule covalently bound to a cytotoxic agent or which is a radiolabelled organic molecule.

### Claim 16

A method for treatment or diagnosis of a pathological condition wherein said method comprises the administration, to a person or animal in need of said treatment or diagnosis, of an effective amount of radiolabelled 4,4-bis(4-hydroxy-3,5-diiodophenyl)pentanoic acid, radiolabelled N-(4-hydroxy-3,5-diiodobenzoyl)-1,6-hexanediamine.

### Claim 17

A pharmaceutical or diagnostic composition comprising a bifunctional antibody having affinity for a tumour and for a therapeutic or diagnostic agent, wherein the agent is an organic molecule.

### Claim 18 (depends on 17)

The composition, according to claim 17, wherein said composition is a pharmaceutical composition.

### Claim 19 (depends on 17)

The composition, according to claim 17, wherein said composition is a diagnostic composition.

### Claim 20

A method for treating cancer wherein said method comprises administering to a human or animal in need of such treatment an effective amount of a bifunctional antibody having affinity for a tumour and for a therapeutic or diagnostic agent, wherein the agent is an organic molecule.

### Claim 21

A diagnostic procedure wherein said procedure utilizes a bifunctional antibody having affinity for a tumour and for a therapeutic or diagnostic agent, wherein the agent is an organic molecule to detect a condition.
